Insilico Medicine (Insilico Medicine, HKEX: 03696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), announced that ISM4808, an AI-driven PHD inhibitor for ...
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. Well, the first step is diagnosis. We have ...
Ferumoxytol, an injection formulation of iron, is a promising treatment for iron deficiency-related anemia. The drug was approved by the FDA in June. Ajay K. Singh, MD, Director of Dialysis Services ...
Credit: Getty Images. Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. The Food and Drug Administration (FDA) has approved Jesduvroq (daprodustat) for the treatment of ...
The US Food and Drug Administration (FDA) has approved daprodustat (Jesduvroq), the first oral treatment for anemia caused by chronic kidney disease (CKD) in adults who have been on dialysis for at ...
Expands access to much-needed iron therapy for millions of US patients Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches Strengthens US supply of ...
The Food and Drug Administration has given Viatris permission for iron sucrose injection, an intravenous iron replacement product used to treat iron deficiency anemia in adult and pediatric patients ...
A 45-year-old woman with stage 5 chronic kidney disease (CKD) due to lupus nephritis visits the nephrology clinic for routine follow-up. She has no overt uremic symptoms. There is no shortness of ...
Turns out, the third time is the charm. After two prior FDA rejections for oral anemia drugs in the hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) drug class, GSK’s daprodustat, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results